Tecadenoson | CVT-510 | CAS#204512-90-3 | adenosine A1 receptor agonist

MedKoo Cat#: 326957 | Name: Tecadenoson

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tecadenoson, also known as CVT-510, is an adenosine A1 receptor agonist potentially for the treatment of paroxysmal supraventricular tachycardia. Tecadenoson appears to be an effective agent for producing rapid and sustained conversion of PSVT to sinus rhythm.

Chemical Structure

Tecadenoson

CAS#204512-90-3

Theoretical Analysis

MedKoo Cat#: 326957

Name: Tecadenoson

CAS#: 204512-90-3

Chemical Formula: C14H19N5O5

Exact Mass: 337.1386

Molecular Weight: 337.34

Elemental Analysis: C, 49.85; H, 5.68; N, 20.76; O, 23.71

Price and Availability

Size	Price	Availability
5mg	USD 650.00	2 Weeks
10mg	USD 1,000.00	2 Weeks
25mg	USD 1,600.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Tecadenoson; CVT-510; CVT 510; CVT510.

IUPAC/Chemical Name

(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(((R)-tetrahydrofuran-3-yl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol

InChi Key

OESBDSFYJMDRJY-BAYCTPFLSA-N

InChi Code

InChI=1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)/t7-,8-,10-,11-,14-/m1/s1

SMILES Code

O[C@H]1[C@H](N2C=NC3=C(N[C@H]4COCC4)N=CN=C23)O[C@H](CO)[C@H]1O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 337.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Abdalla M, Rabie AM. Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant. Comput Biol Chem. 2023 Jun;104:107768. doi: 10.1016/j.compbiolchem.2022.107768. Epub 2022 Sep 7. PMID: 36842392; PMCID: PMC9450471. 2: Rabie AM, Abdalla M. A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study. ChemistrySelect. 2022 Dec 13;7(46):e202201912. doi: 10.1002/slct.202201912. Epub 2022 Dec 8. PMID: 36718467; PMCID: PMC9877610. 3: Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529/BA.2 subvariant: A repurposing research study. Med Chem Res. 2023;32(2):326-341. doi: 10.1007/s00044-022-02970-3. Epub 2022 Dec 29. PMID: 36593869; PMCID: PMC9797896. 4: Hijikata A, Shionyu-Mitsuyama C, Nakae S, Shionyu M, Ota M, Kanaya S, Shirai T. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. FEBS Lett. 2020 Jun;594(12):1960-1973. doi: 10.1002/1873-3468.13806. Epub 2020 May 25. PMID: 32379896; PMCID: PMC7267562. 5: Dinh W, Albrecht-Küpper B, Gheorghiade M, Voors AA, van der Laan M, Sabbah HN. Partial Adenosine A1 Agonist in Heart Failure. Handb Exp Pharmacol. 2017;243:177-203. doi: 10.1007/164_2016_83. PMID: 27770217. 6: Corino VD, Sandberg F, Mainardi LT, Platonov PG, Sörnmo L. Noninvasive characterization of atrioventricular conduction in patients with atrial fibrillation. J Electrocardiol. 2015 Nov-Dec;48(6):938-42. doi: 10.1016/j.jelectrocard.2015.08.010. Epub 2015 Aug 4. PMID: 26324177. 7: Corino VD, Sandberg F, Mainardi LT, Platonov PG, Sörnmo L. Noninvasive Assessment of Atrioventricular Nodal Function: Effect of Rate-Control Drugs during Atrial Fibrillation. Ann Noninvasive Electrocardiol. 2015 Nov;20(6):534-41. doi: 10.1111/anec.12253. Epub 2014 Dec 26. PMID: 25545540; PMCID: PMC6931421. 8: Szentmiklosi AJ, Galajda Z, Cseppento Á, Gesztelyi R, Susán Z, Hegyi B, Nánási PP. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. Curr Pharm Des. 2015;21(8):965-76. doi: 10.2174/1381612820666141029100346. PMID: 25354187. 9: Corino VD, Holmqvist F, Mainardi LT, Platonov PG. Beta-blockade and A1-adenosine receptor agonist effects on atrial fibrillatory rate and atrioventricular conduction in patients with atrial fibrillation. Europace. 2014 Apr;16(4):587-94. doi: 10.1093/europace/eut251. Epub 2013 Aug 29. PMID: 23989533. 10: Lepist EI, Damaraju VL, Zhang J, Gati WP, Yao SY, Smith KM, Karpinski E, Young JD, Leung KH, Cass CE. Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22. doi: 10.1124/dmd.112.049858. Epub 2013 Feb 6. PMID: 23388705. 11: Mor M, Shalev A, Dror S, Pikovsky O, Beharier O, Moran A, Katz A, Etzion Y. INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67. doi: 10.1124/jpet.112.200873. Epub 2012 Oct 10. PMID: 23055540. 12: Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23. PMID: 21185259; PMCID: PMC3437328. 13: Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol. 2009;(193):25-58. doi: 10.1007/978-3-540-89615-9_2. PMID: 19639278. 14: Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10. doi: 10.1517/13543780802497284. PMID: 19012505. 15: Cappellacci L, Franchetti P, Vita P, Petrelli R, Lavecchia A, Costa B, Spinetti F, Martini C, Klotz KN, Grifantini M. 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem. 2008 Jan 1;16(1):336-53. doi: 10.1016/j.bmc.2007.09.035. Epub 2007 Sep 22. PMID: 17933541. 16: Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):707-14. doi: 10.1586/14779072.5.4.707. PMID: 17605649. 17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 May;28(4):233-77. PMID: 16801985. 18: Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev. 2005 Nov-Dec;13(6):315-21. doi: 10.1097/01.crd.0000181621.84565.9d. PMID: 16230891. 19: Ellenbogen KA, O'Neill G, Prystowsky EN, Camm JA, Meng L, Lieu HD, Jerling M, Shreeniwas R, Belardinelli L, Wolff AA; TEMPEST Study Group. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation. 2005 Jun 21;111(24):3202-8. doi: 10.1161/CIRCULATIONAHA.104.510982. Epub 2005 Jun 13. PMID: 15956124. 20: Palle VP, Varkhedkar V, Ibrahim P, Ahmed H, Li Z, Gao Z, Ozeck M, Wu Y, Zeng D, Wu L, Leung K, Chu N, Zablocki JA. Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF). Bioorg Med Chem Lett. 2004 Jan 19;14(2):535-9. doi: 10.1016/j.bmcl.2003.09.094. PMID: 14698198.